BioTuesdays

Category - Markets

Markets

HCW ups Cesca Therapeutics PT to $6.50 from $1

H.C. Wainwright raised its price target for Cesca Therapeutics (NASDAQ:KOOL) to $6.50 from $1 after the company’s second quarter revenue beat consensus. The stock closed at $3 on Aug. 13. Cesca develops and markets...

August 14, 2019
Mustang Bio Logo
Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019
Ra Medical
Markets

Piper cuts Ra Medical to neutral; PT to $1.50 from $9

Piper Jaffray downgraded Ra Medical Systems (NASDAQ:RMED) to “neutral” from “overweight” and slashed its price target to $1.50 from $9 after the company disclosed several operating issues in its preliminary second...

August 13, 2019
Fulcrum Therapeutics
Markets

SVB Leerink starts Fulcrum Therapeutics at OP; PT $20

SVB Leerink initiated coverage of Fulcrum Therapeutics (NASDAQ:FULC) with an “outperform” rating and price target of $20 in 12 months. The stock closed at $11.62 on Aug. 9. Fulcrum is a clinical-stage biopharmaceutical...

August 12, 2019
Melinta Therapeutics
Markets

HCW cuts Melinta Therapeutics to neutral and removes PT

H.C. Wainwright downgraded Melinda Therapeutics (NASDAQ:MLNT) to “neutral” from “buy” and removed its price target after the company’s chairman and CEO abruptly resigned on Aug. 9, when the stock dropped 67 cents to...

August 12, 2019
Markets

WB starts Phreesia at OP

William Blair launched coverage of Phreesia (NYSE:PHR) with an “outperform” rating. The stock closed at $27.37 on Aug. 9. Phreesia, which went public in July 2019, gives healthcare organizations a suite of robust...

August 12, 2019
Autolus Logo
Markets

HCW cuts Autolus PT to $24 from $41

H.C. Wainwright lowered its price target for Autolus Therapeutics plc (NASDAQ:AUTL) to $24 from $41 after significant changes to its pipeline and timelines were disclosed in the company’s second quarter results. The...

August 12, 2019
Precision Biosciences
Markets

BTIG starts Precision BioSciences at buy; PT $22

BTIG initiated coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $22 price target, representing upside of approximately 100% from a closing price of $10.98 on Aug. 8. “While Precision only recently...

August 9, 2019
ViewRay Logo
Markets

BTIG cuts ViewRay PT to $6 from $10

BTIG lowered its price target for ViewRay (NASDAQ:VRAY) to $6 from $10 after the company reported second quarter results. The stock closed at $6.74 on Aug. 8 but was down to $3.35 in after hours trading. ViewRay, which...

August 9, 2019
Markets

WB starts Addus HomeCare at OP

William Blair initiated coverage of Addus HomeCare (NASDAQ:ADUS) with an “outperform” rating, saying the company is one of the few ways for public market investors to play the in-home healthcare delivery theme, with a...

August 9, 2019